Carlyle and SK Capital Partners announced on April 16, 2025, an extension of the expiration date for their tender offer to acquire bluebird bio, Inc. The offer, previously set to expire on April 18, 2025, has been extended to one minute after 11:59 p.m. New York City time on May 2, 2025.
The extension is intended to allow additional time for the satisfaction of remaining conditions to the tender offer, primarily the receipt of applicable regulatory approvals. As of the close of business on April 15, 2025, approximately 700,288 shares of bluebird common stock had been validly tendered.
Holders who have already tendered their shares are not required to re-tender or take any further action in response to this extension. The ongoing process highlights the complexities involved in securing all necessary clearances for significant acquisitions in the biotechnology sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.